Three independent discounted-cash-flow-style models value Boston Scientific Corp. every trading day. 1 of 3 currently price BSX above its market price.
| Free Cash Flow model | $49.47 |
| Excess Profit model | $27.94 |
| Residual Earnings model | $5.22 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +7.5% |
| Net debt / EBITDA | 3.3× |
| Gross margin | +69.0% |
| Revenue CAGR | +16.5% |
| Cash conversion | 1.6× |
| Dividend yield | — |
| Buyback yield | -0.6% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BSX in StockKitty